

Supplementary table 1. Relative expression of miRNA in plasma and bile among individuals with PDAC, CP, and controls

| Candidate miRNA | PDAC | CP | Normal | P value | PDAC vs. CP | PDAC vs. Normal | CP vs. Normal |
|---------------------------------|-----------------|-------------|-------------|---------|-------------|-----------------|---------------|
| Training Cohort - Plasma | | | | | | | |
| | N=40 | N=30 | N=24 | | | | |
| miR-10b | 13.1 (13.2) | 0.9 (1.2) | 1.1 (0.6) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 21.2 (30.8) | 1.2 (0.8) | 1.0 (0.4) | | | | |
| miR-21 | 0.9 (0.7) | 1.2 (1.7) | 0.8 (0.7) | 0.426 | | | |
| | 1.0 (0.8) | 1.5 (1.4) | 1.0 (0.6) | | | | |
| miR-30c | 8.4 (11.8) | 1.3 (3.0) | 0.8 (0.8) | <0.001 | <0.001 | <0.001 | 0.126 |
| | 14.5 (18.8) | 2.2 (2.1) | 1.0 (0.7) | | | | |
| miR-106b | 8.4 (13.6) | 1.4 (1.2) | 0.9 (0.9) | <0.001 | <0.001 | <0.001 | 0.378 |
| | 14.2 (12.3) | 1.4 (0.9) | 1.0 (0.6) | | | | |
| miR-132 | 1.9 (2.8) | 1.0 (1.2) | 0.7 (0.7) | 0.001 | 0.073 | 0.001 | 0.341 |
| | 2.4 (1.8) | 1.5 (1.4) | 1.0 (0.9) | | | | |
| miR-155 | 164.1 (826.8) | 1.1 (2.1) | 1.1 (0.8) | <0.001 | <0.001 | <0.001 | 0.558 |
| | 1051.1 (2080.2) | 2.4 (2.9) | 1.0 (0.6) | | | | |
| miR-181a | 2.0 (2.4) | 1.0 (1.3) | 1.0 (0.7) | 0.007 | 0.016 | 0.025 | 1.000 |
| | 2.6 (3.5) | 1.1 (0.9) | 1.0 (0.5) | | | | |
| miR-181b | 1.8 (1.9) | 0.5 (0.5) | 0.9 (0.6) | <0.001 | <0.001 | 0.001 | 0.096 |
| | 2.2 (1.5) | 0.7 (0.7) | 1.0 (0.6) | | | | |
| miR-196a | 2.0 (3.1) | 0.6 (0.9) | 0.8 (1.2) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 2.8 (2.5) | 1.2 (1.7) | 1.0 (0.9) | | | | |
| miR-212 | 7.3 (6.7) | 1.0 (1.5) | 0.8 (0.9) | <0.001 | <0.001 | <0.001 | 0.578 |
| | 7.3 (5.0) | 1.7 (1.9) | 1.0 (0.9) | | | | |
| Training cohort - bile | | | | | | | |
| | N=25 | N=23 | N=22 | | | | |
| miR-10b | 10.2 (8.6) | 0.7 (1.0) | 1.0 (0.5) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 19.5 (27.0) | 1.1 (0.7) | 1.0 (0.4) | | | | |
| miR-21 | 1.4 (1.4) | 1.3 (1.3) | 1.0 (0.6) | 0.151 | | | |
| | 1.5 (1.0) | 1.5 (1.1) | 1.0 (0.4) | | | | |
| miR-30c | 11.3 (8.5) | 1.5 (1.2) | 1.0 (0.6) | <0.001 | <0.001 | <0.001 | 0.051 |
| | 13.7 (9.4) | 1.6 (1.1) | 1.0 (0.5) | | | | |
| miR-106b | 19.9 (19.7) | 1.2 (1.3) | 1.1 (0.4) | <0.001 | <0.001 | <0.001 | 0.622 |
| | 25.0 (19.9) | 1.5 (1.1) | 1.1 (0.6) | | | | |
| miR-132 | 1.2 (1.6) | 1.0 (1.1) | 1.1 (0.7) | 0.535 | | | |
| | 1.5 (1.1) | 1.1 (1.0) | 1.2 (1.2) | | | | |
| miR-155 | 24.7 (20.2) | 1.1 (1.2) | 0.9 (0.4) | <0.001 | <0.001 | <0.001 | 0.761 |
| | 31.5 (26.8) | 1.2 (0.8) | 1.0 (0.4) | | | | |
| miR-181a | 1.5 (1.1) | 1.2 (1.1) | 1.0 (0.4) | 0.016 | 0.115 | 0.015 | 1.000 |

| | | | | | | | |
|-----------------------------------|-------------------|-------------|-------------|--------|--------|--------|--------|
| | 1.8 (1.3) | 1.2 (0.8) | 1.0 (0.4) | | | | |
| miR-181b | 1.1 (1.0) | 1.3 (1.1) | 1.0 (0.8) | 0.297 | | | |
| | 1.5 (1.1) | 1.5 (1.0) | 1.1 (0.7) | | | | |
| miR-196a | 1.6 (1.0) | 1.2 (0.9) | 0.9 (0.8) | 0.009 | 0.198 | 0.006 | 0.527 |
| | 1.9 (1.3) | 1.3 (0.9) | 1.0 (0.5) | | | | |
| miR-212 | 10.7 (8.5) | 1.0 (0.9) | 0.8 (0.7) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 12.2 (6.6) | 1.2 (0.8) | 1.1 (0.5) | | | | |
| | | | | | | | |
| Validation Cohort - Plasma | | | | | | | |
| | N=29 | N=37 | N=38 | | | | |
| miR-10b | 31.5 (58.5) | 1.0 (1.0) | 1.0 (0.7) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 70.4 (93.4) | 1.2 (0.7) | 1.0 (0.6) | | | | |
| miR-30c | 11.6 (12.7) | 1.3 (1.2) | 0.9 (1.1) | <0.001 | <0.001 | <0.001 | 0.942 |
| | 13.1 (10.0) | 1.4 (0.8) | 1.3 (1.0) | | | | |
| miR-106b | 19.4 (12.8) | 1.1 (1.4) | 0.7 (1.0) | <0.001 | <0.001 | <0.001 | 0.851 |
| | 22.4 (16.7) | 1.2 (1.0) | 0.9 (0.7) | | | | |
| miR-155 | 80.2 (717.6) | 1.5 (1.7) | 1.0 (0.5) | <0.001 | <0.001 | <0.001 | <0.001 |
| | 841.2 (1428.2) | 2.0 (1.6) | 1.1 (0.8) | | | | |
| miR-212 | 13.9 (12.4) | 1.2 (1.1) | 0.8 (0.7) | <0.001 | <0.001 | <0.001 | 0.003 |
| | 17.4 (12.7) | 1.5 (0.8) | 0.9 (0.5) | | | | |
| Validation cohort - bile | | | | | | | |
| | N=28 | N=28 | N=33 | | | | |
| miR-10b | 9.6 (7.1) | 1.0 (0.7) | 1.0 (0.6) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 14.0 (14.8) | 1.1 (0.7) | 1.0 (0.4) | | | | |
| miR-30c | 7.3 (5.9) | 1.1 (1.0) | 1.0 (0.5) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 10.4 (10.0) | 1.3 (0.9) | 1.0 (0.4) | | | | |
| miR-106b | 11.3 (12.4) | 1.2 (1.1) | 1.1 (0.7) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 16.0 (16.5) | 1.3 (0.8) | 1.1 (0.5) | | | | |
| miR-155 | 21.0 (25.9) | 0.9 (1.0) | 0.8 (0.8) | <0.001 | <0.001 | <0.001 | 0.468 |
| | 31.6 (28.4) | 1.2 (0.8) | 1.0 (0.7) | | | | |
| miR-212 | 8.1 (6.1) | 0.9 (0.4) | 1.0 (0.4) | <0.001 | <0.001 | <0.001 | 1.000 |
| | 9.4 (5.4) | 0.9 (0.3) | 0.9 (0.4) | | | | |

All miRNA levels are nonparametric and hence median (interquartile range) is reported. We also include mean (standard deviation) in gray font for descriptive purposes. P-values are obtained based using the Kruskal-Wallis test and pairwise p-values are adjusted using the Bonferroni multiple comparison approach.

Supplementary Table 2. Performance characteristics of miRNA for distinguishing PDAC from CP and control subjects (training cohort, n=95)

| Candidate miRNA | PDAC vs. CP | PDAC vs. Control | CP vs. Control | PDAC vs. Other | Threshold |
|-----------------|-------------|------------------|----------------|----------------|--------------|
| Plasma | | | | | |
| miR-10b | 0.982 | 1.000 | 0.494 | 0.980 | 3.579 |
| miR-21 | 0.589 | 0.485 | 0.572 | 0.556 | |
| miR-30c | 0.902 | 0.984 | 0.625 | 0.938 | 4.873 |
| miR-106b | 0.998 | 1.000 | 0.609 | 0.999 | 2.92 |
| miR-132 | 0.659 | 0.757 | 0.634 | 0.703 | |
| miR-155 | 0.971 | 0.979 | 0.601 | 0.975 | 10.68 |
| miR-181a | 0.687 | 0.698 | 0.495 | 0.692 | |
| miR-181b | 0.873 | 0.786 | 0.680 | 0.834 | |
| miR-196a | 0.763 | 0.773 | 0.466 | 0.767 | |
| miR-212 | 0.878 | 0.927 | 0.596 | 0.900 | 2.013 |
| Bile | | | | | |
| miR-10b | 0.974 | 0.965 | 0.458 | 0.970 | 3.497 |
| miR-21 | 0.485 | 0.645 | 0.646 | 0.578 | |
| miR-30c | 0.991 | 1.000 | 0.678 | 0.996 | 3.933 |
| miR-106b | 0.983 | 0.991 | 0.597 | 0.987 | 5.261 |
| miR-132 | 0.590 | 0.562 | 0.538 | 0.576 | |
| miR-155 | 0.986 | 0.995 | 0.586 | 0.990 | 5.232 |
| miR-181a | 0.671 | 0.733 | 0.569 | 0.701 | |
| miR-181b | 0.550 | 0.580 | 0.636 | 0.513 | |
| miR-196a | 0.637 | 0.772 | 0.599 | 0.703 | |
| miR-212 | 0.981 | 0.982 | 0.538 | 0.981 | 4.163 |


AUC = Area under the curve;

Threshold denotes the miRNA expression level corresponding to the AUC for PDAC vs. All other (CP + controls).

For reference, accuracy is graded from fail to excellent based on the following AUC thresholds:

| Accuracy | AUC |
|-----------|--------|
| Excellent | ≥ 0.90 |
| Good | ≥ 0.80 |
| Fair | ≥ 0.70 |
| Poor | ≥ 0.60 |
| Fail | < 0.60 |

Supplemental Figure 1. Plasma and bile miRNA expression by smoking status




Differential expression of miRNA in plasma (top panel) and bile (bottom panel) is illustrated as a function of smoking status (never, ever, or current). The inclusion of smoking status in our regression models to establish Signature Panels did not impact the results.

Supplemental Figure 2. Plasma and bile miRNA expression by serum bilirubin elevation



Differential expression of miRNA in plasma (top panel) and bile (bottom panel) is illustrated as a function of serum bilirubin elevation, defined as $> 2\text{mg/dL}$. The inclusion of serum bilirubin in our regression models to establish Signature Panels did not impact the results.

Supplemental Figure 3. Plasma and bile miRNA expression by age



Differential expression of miRNA in plasma (top panel) and bile (bottom panel) is illustrated as a function of age. The inclusion of age in our regression models to establish Signature Panels did not impact the results.